Patent innovation strengthens Adial Pharmaceuticals in the fight against alcohol addiction.

Adial Pharmaceuticals has made a significant advancement in its mission to combat alcohol dependence through innovative genetic insights. A new patent, soon to be granted, is expected to expand the intellectual property protection surrounding the company's main research program, AD04. This developmental drug, targeting the treatment of alcohol use disorder (AUD), is based on a precise medical approach. Thanks to a proprietary genetic diagnostic solution, the new patent covers additional genotype combinations that aim to improve the precision of treatment with AD04. The CEO of Adial Pharmaceuticals, Cary Claiborne, described the patent approval as a significant milestone that underscores the company's strategy to expand its patent portfolio. AD04, a genetically tailored antagonist of the serotonin-3 receptor, was recently investigated in the ONWARD Phase 3 trial. This study aims to evaluate the potential of AD04 to treat AUD in patients with specific genotypes identified through the company’s genetic testing procedure. In August, Adial announced that the last patient completed their participation in the pharmacokinetics study of AD04. Results are expected in the fourth quarter of 2024. Earlier, in April, Adial had already expanded its intellectual property protection with another US patent covering the combination of genetic diagnostics to identify patients with specific genotypes. Following the patent granting, the further development of AD04 for the treatment of AUD will be closely monitored, with investors keenly observing the potential impact on stock prices.